Pan-tumor MRD Study

September 22, 2026 updated by: Paradigm Health

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.

Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1350

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35205
    • Arizona
      • Bullhead City, Arizona, United States, 86442
        • Recruiting
        • Mohtaseb Cancer Center and Blood Disorders
        • Principal Investigator:
          • Hamdy Mohtaseb
        • Contact:
      • Casa Grande, Arizona, United States, 85122
        • Recruiting
        • Cancer & Blood Specialists of Arizona
        • Contact:
        • Principal Investigator:
          • Carlos Arce-Lara
    • Arkansas
      • Little Rock, Arkansas, United States, 72205
        • Recruiting
        • CARTI
        • Contact:
        • Principal Investigator:
          • Andrew Briggler
      • Springdale, Arkansas, United States, 72762
        • Recruiting
        • Highlands Oncology Group (HOG)
        • Principal Investigator:
          • Joseph Beck
        • Contact:
    • California
      • Glendale, California, United States, 91204
        • Recruiting
        • Los Angeles Cancer Network (LACN)
        • Contact:
        • Principal Investigator:
          • Peyman Salimi-Tari
      • Oxnard, California, United States, 93030
        • Recruiting
        • Ventura County Hematology Oncology Specialists
        • Contact:
        • Principal Investigator:
          • Lynn Kong
      • San Diego, California, United States, 92123
      • San Diego, California, United States, 92123
        • Recruiting
        • Medical Oncology Associates of San Diego (MOASD)
        • Contact:
        • Principal Investigator:
          • James Coggan
      • Stockton, California, United States, 95204
        • Recruiting
        • Stockton Hematology Oncology Med Group
        • Contact:
        • Principal Investigator:
          • Sunny Phillip
    • Colorado
      • Englewood, Colorado, United States, 80113
    • Florida
      • Coral Springs, Florida, United States, 33065
        • Recruiting
        • Oncology & Hematology Associates of West Broward
        • Principal Investigator:
          • Sumit Sawhney
        • Contact:
      • Orange City, Florida, United States, 32763
        • Recruiting
        • Mid Florida Cancer Centers
        • Principal Investigator:
          • Santosh Nair
        • Contact:
      • St. Petersburg, Florida, United States, 33709
        • Recruiting
        • Comprehensive Hematology Oncology (CHO)
        • Principal Investigator:
          • Neeharika Makani
        • Contact:
    • Georgia
      • Atlanta, Georgia, United States, 30318
        • Recruiting
        • Piedmont Cancer Institute
        • Contact:
        • Principal Investigator:
          • Vasileios Assikis
    • Illinois
      • O'Fallon, Illinois, United States, 62269
        • Recruiting
        • Cancer Care Specialists of Illinois (CCSI)
        • Principal Investigator:
          • James Wade
        • Contact:
      • Urbana, Illinois, United States, 61801
        • Recruiting
        • Carle Health
        • Contact:
        • Principal Investigator:
          • Christine Canfield
    • Kansas
      • Topeka, Kansas, United States, 66606
        • Recruiting
        • Cotton O'Neil Cancer Center [Stormont Vail]
        • Contact:
        • Principal Investigator:
          • Mehmmod Hashmi
      • Wichita, Kansas, United States, 67214
    • Kentucky
      • Corbin, Kentucky, United States, 40701
        • Recruiting
        • Baptist Health Corbin
        • Contact:
        • Principal Investigator:
          • Abigail Byrnes
      • Elizabethtown, Kentucky, United States, 42701
        • Recruiting
        • Baptist Health Hardin
        • Contact:
        • Principal Investigator:
          • Christopher Burkeen
      • Lexington, Kentucky, United States, 40503
        • Recruiting
        • Baptist Health Lexington
        • Principal Investigator:
          • Arvinda Padmanabhan
        • Contact:
      • Louisville, Kentucky, United States, 40207
        • Recruiting
        • Baptist Health Louisville
        • Principal Investigator:
          • Wangjian Zhong
        • Contact:
    • Louisiana
      • Covington, Louisiana, United States, 70433
        • Recruiting
        • Pontchartrain Cancer Center
        • Principal Investigator:
          • David Oubre
        • Contact:
      • Shreveport, Louisiana, United States, 71105
        • Recruiting
        • Christus Health Highlands
        • Contact:
        • Principal Investigator:
          • Neelima Chintapalli
    • Michigan
      • Grand Rapids, Michigan, United States, 49546
        • Recruiting
        • The Cancer & Hematology Centers (CHC)
        • Contact:
        • Principal Investigator:
          • Joy Bartholomew
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic
        • Contact:
        • Principal Investigator:
          • Lisa Boardman
    • Missouri
      • Springfield, Missouri, United States, 65807
        • Recruiting
        • Cox Health
        • Contact:
        • Principal Investigator:
          • Rajesh Banderudrappagari
    • Nebraska
      • Lincoln, Nebraska, United States, 68516
        • Recruiting
        • Cancer Partners of Nebraska
        • Contact:
        • Principal Investigator:
          • Stacey Knox
    • New Mexico
      • Farmington, New Mexico, United States, 87401
        • Recruiting
        • San Juan Oncology Associates
        • Principal Investigator:
          • Sardar Imam
        • Contact:
    • New York
      • Binghamton, New York, United States, 13905
        • Recruiting
        • Guthrie Lourdes Memorial Hospital (GLMH)
        • Principal Investigator:
          • Beka Aroshidze
        • Contact:
      • Shirley, New York, United States, 11967
        • Recruiting
        • New York Cancer & Blood Specialists
        • Principal Investigator:
          • Richard Zuniga
        • Contact:
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
        • Recruiting
        • Carolina Oncology Specialists
        • Principal Investigator:
          • Justin Favaro
        • Contact:
      • Goldsboro, North Carolina, United States, 27534
        • Recruiting
        • Southeastern Medical Oncology Center (SMOC)
        • Contact:
        • Principal Investigator:
          • Samer Kasbari
      • Wilson, North Carolina, United States, 27893
        • Recruiting
        • Regional Medical Oncology Center
        • Principal Investigator:
          • Keith Lerro
        • Contact:
    • Ohio
      • Canton, Ohio, United States, 44718
        • Recruiting
        • Gabrail Cancer Center
        • Principal Investigator:
          • Nashat Gabrail
        • Contact:
      • Maumee, Ohio, United States, 43437
        • Recruiting
        • Taylor Cancer Research Center
        • Contact:
    • Oklahoma
      • Tulsa, Oklahoma, United States, 74129
        • Recruiting
        • Oklahoma Cancer Specialists and Research Institute (OCSRI)
        • Contact:
        • Principal Investigator:
          • Scott Cole
    • Oregon
      • Portland, Oregon, United States, 97201
        • Recruiting
        • Oregon Health & Science University (OHSU)
        • Principal Investigator:
          • Nima Nabavizadeh
        • Contact:
    • Pennsylvania
      • Lancaster, Pennsylvania, United States, 17601
      • Sayre, Pennsylvania, United States, 18840
        • Recruiting
        • Guthrie Foundation
        • Contact:
        • Principal Investigator:
          • Rebekah Macfie
      • York, Pennsylvania, United States, 17403
        • Recruiting
        • Cancer Care Associates of York (CCAY)
        • Principal Investigator:
          • Chanh Huynh
        • Contact:
    • Texas
      • Houston, Texas, United States, 77030
        • Recruiting
        • Onocology Consultants P.A. (Oncology Consultants [OC Houston])
        • Principal Investigator:
          • Julio Peguero
        • Contact:
      • Kingwood, Texas, United States, 77339
        • Recruiting
        • Community Clinical Trials
        • Principal Investigator:
          • Saleha Sajid
        • Contact:
      • Texarkana, Texas, United States, 75503
    • Virginia
      • Richmond, Virginia, United States, 23229
        • Recruiting
        • Virginia Cancer Institute
        • Contact:
        • Principal Investigator:
          • Susan Moore
    • Washington
      • Tacoma, Washington, United States, 98405
        • Recruiting
        • Northwest Medical Specialties (NWMS)
        • Contact:
        • Principal Investigator:
          • Manas Agastya

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Description

Eligibility Criteria:

  1. Age 18 years or older.

  2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).

  3. Eligible for curative intent therapy, with surgical resection of cancer planned.

    a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.

  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.

  5. No systemic therapy for current cancer diagnosis administered before enrollment.

  6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.

  7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).

  8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.

  9. No prior allogeneic hematopoietic stem cell transplant.

  10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.

    Cohort Specific Criteria

  11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:

  12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.

  13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.

  14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.

The following tumor types are excluded:

  1. Central nervous system (CNS) malignancies

  2. Colorectal cancer

  3. Breast cancer

  4. Squamous cell skin cancer

  5. Basal cell carcinoma

  6. Gastrointestinal stromal tumors (GIST)

  7. Thyroid cancer

  8. Uveal melanoma

  9. Low or intermediate grade neuroendocrine tumors

    ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible

  10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

routine standard of care

Routine standard of care

Esophageal

Esophageal cancer

routine standard of care

Routine standard of care

Gastric and Gastroesophageal Junction (GEJ)

Gastric and Gastroesophageal Junction (GEJ)

routine standard of care

Routine standard of care

Melanoma

Melanoma

routine standard of care

Routine standard of care

Non-small cell lung (NSCLC)

Non-small cell lung (NSCLC)

routine standard of care

Routine standard of care

Pancreatic (exocrine only)

Pancreatic (exocrine only)

routine standard of care

Routine standard of care

Mix of Solid Tumors (MOST)

Mix of Solid Tumors (MOST)

routine standard of care

Routine standard of care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood and tissue biospecimen registry
Time Frame: Observation from enrollment to 5.5 years after enrollment

To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

Observation from enrollment to 5.5 years after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 8, 2025

Primary Completion (Estimated)

December 1, 2031

Study Completion (Estimated)

April 1, 2032

Study Registration Dates

First Submitted

September 18, 2024

First Submitted That Met QC Criteria

September 18, 2024

First Posted (Actual)

September 20, 2024

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.